Elan Prialt NDA Awaits Longer-Term Data In Chronic Pain
Elan is planning a long-term study of the chronic pain treatment Prialt (ziconotide) to supplement its pending NDA, the company told a Feb. 4 conference call
Elan is planning a long-term study of the chronic pain treatment Prialt (ziconotide) to supplement its pending NDA, the company told a Feb. 4 conference call